SMO ClinPlus Co., Ltd. Class A

SMO ClinPlus Co., Ltd. Class A

SSZSE:301257
32.48
CNY
-0.78
(-2.35%)
0.37EPS
114.22P/E
3.37BMarket Cap
May 04Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
23.95
3.2
4.84
8.96
3.28
5.17
5.77
8.57
8.41
9.7
10.19
10.6
10.34
Basic EPS, GAAP
3.68
-0.49
0.5
1.43
0.52
0.89
0.61
0.98
1.04
1.72
1.35
1.38
0.37
Free Cash Flow per Basic Share
1.68
0.39
-0.13
2.09
0.35
0.69
0.32
0.63
0.47
1.34
-0.13
0.35
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.14
0.28
0.17
0.07
Book Value per Share
0.63
1.12
1.73
3.27
5.36
2.14
2.82
3.91
12.01
13.59
14.76
16.07
16.08
Tangible Book Value per Share
0.63
1.11
1.73
3.26
5.34
2.14
2.82
3.91
12
13.56
14.73
16.05
16.06
Basic Weighted Avg Shares
1
13
13
13
59
59
58
59
70
78
79
79
79
Sales/Revenue/Turnover
31
42
63
116
193
304
335
503
586
760
804
843
820
Operating Margin (%)
21.92
-9.83
16.33
20.22
18.9
20.14
13.99
14.58
13.54
20.4
14.32
15.95
5.33
Depreciation Expense
- -
- -
1
1
1
2
2
7
8
11
13
16
- -
Net Income, GAAP
5
-6
6
19
30
52
35
58
72
135
106
110
30
Effective Tax Rate (%)
25
- -
29.39
16.79
12.16
13.63
14.92
13.62
10.42
16.33
12.46
14.26
30
Profit Margin (%)
15.38
-15.37
10.33
15.98
15.7
17.25
10.53
11.49
12.35
17.73
13.24
13.01
3.62
Working Capital
8
11
20
39
65
110
145
204
924
1,046
1,134
1,048
956
LT Debt
- -
- -
- -
- -
- -
- -
2
1
- -
5
1
1
1
Total Equity
8
15
22
43
70
125
165
229
952
1,081
1,173
1,270
1,271
Return on Invested Capital (%)
- -
- -
34.5
62.36
64.7
65.76
26.46
28.38
12.04
13.08
9.31
8.91
2.43
Return on Capital (%)
- -
- -
35.14
57.19
53.55
53.47
23.93
28.75
12.2
13.18
9.41
8.95
2.39
Return on Common Equity (%)
- -
-56.52
35.14
57.19
53.99
53.74
24.34
29.34
12.26
13.26
9.44
8.98
2.38

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
79
79
79
Market Capitalization
4,382
3,585
3,374

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,210
1,217
1,204
Cash, Cash Equivalents & STI
579
577
550
Accounts Receivable, Net
144
180
185
Inventories
- -
- -
- -
Total Current Liabilities
242
263
248
Payables & Accruals
- -
- -
- -
ST Debt
3
3
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.44%
77%
8.21%
Free Cash Flow
-201.74%
-33.79%
-370.74%
Net Income, GAAP
24.48%
31.4%
3.01%
Sales/Revenue/Turnover
37.63%
21.36%
4.82%
Total Cash Common Dividend
- -
- -
-39.66%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
185
210
199
210
804
2025
176
214
- -
233
843
2026
194
178
214
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.38
0.41
0.22
0.43
1.35
2025
0.09
0.6
- -
0.28
1.38
2026
0.15
-0.12
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.15
0.28
2025
- -
- -
- -
0.07
0.17
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hong Wei Yang
Full Time Employees
4,372
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Shanghai China
IPO Date
May 17, 2022
Business
SMO ClinPlus Co., Ltd. Class A is a China-based site management organization (SMO) specializing in clinical trial execution and management services for the pharmaceutical, biotechnology, and medical device industries. Founded in 2009 and headquartered in Shanghai, China, the company provides comprehensive clinical research support services to global pharmaceutical multinational corporations, domestic innovative biopharmaceutical developers, and contract research organizations (CROs). The company's core offerings encompass clinical trial execution strategy modeling; site selection and study start-up (SSU) services, including protocol feasibility assessments, ethics committee application filings, site contract negotiations, and trial initiation coordination; on-site clinical research coordinator (CRC) dispatch and execution management, comprising subject screening, patient recruitment and retention, clinical visit coordination, electronic case report form (eCRF) data entry, source document verification, investigational product accountability, and biological sample management; functional service provider (FSP) resourcing models; third-party clinical quality assurance, site audit, and Good Clinical Practice (GCP) compliance training; and institutional site support services, including standard operating procedure development and trial management platform deployment. Operating nationwide across more than 200 Chinese cities and maintaining active collaborations with nearly 1,000 clinical trial institutions, the company supports clinical programs across key therapeutic areas such as oncology, hematology, cardiovascular diseases, endocrinology, dermatology, and infectious diseases. In recent operational and strategic developments, ClinPlus has advanced the technological integration of its service delivery through the deployment of its proprietary Ruixing Clinical Trial Intelligent Management Platform and its registered Ruixing Clinical Trial Text Generation Algorithm, introducing artificial intelligence-enabled automated medical documentation, intelligent patient recruitment modeling, and electronic Trial Master File (e-TMF) quality inspection workflows. Additionally, the company has expanded its early-phase (Phase I and Phase II) clinical trial contract pipeline, increased market share among domestic biopharmaceutical developers pursuing cross-border licensing transactions, and broadened its domestic operating infrastructure through subsidiaries including Ruixin (Ganzhou) Medical Technology Development Co., Ltd.